Drug Trial Radar · NCT04324164
Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC
Last checked: Nov 19, 2026Latest source record: Jan 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
800
Planned (sponsor's estimate)
Start
Mar 24, 2020
Primary completion
Dec 24, 2025
Study completion Dec 24, 2027
Sponsor
- Lead sponsor
- Hunan Province Tumor HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 27, 2020
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to explore Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China
Conditions
- Non-small Cell Lung Cancer
Interventions
Third-generation EGFR-TKIDrug
Third-generation EGFR-TKI including Osimertinib/Furmonertinib/Almonertinib, etc.
EGFR-TKIDrug
All EGFR-TKI
Primary outcomes
What the sponsor says the trial is designed to measure.
- PFSTime frame: 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Yongchang Zhang
Changsha, Hunan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.